Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate relapse activity, as measured by the
proportion of participants relapsed at 12 months, in participants with relapsing-remitting
multiple sclerosis (RRMS) who transition from Tysabri (BG00002) to Tecfidera (BG00012) in the
real-world setting. The secondary objective is to further evaluate relapse activity, defined
as annualized relapse rate (ARR), hospitalization and intravenous corticosteroid use, during
the first year of Tecfidera treatment following transition from Tysabri treatment.